Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines
Regeneron Pharmaceuticals is collaborating with CRISPR technologies startup Mammoth Biosciences to develop in vivo gene-editing therapies. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics.
Examining the Usefulness of the Lean Startup Method in Building Health Tech Products
How health tech startups can successfully adapt the principles to their business ideas
With All the Organ Donation Scrutiny, Ask: What Can We Do to Reduce the Need?
People do not have to die waiting for a kidney. A VBC approach can lead to earlier identification of kidney disease and better management in its earlier stages.
Providence Ordered to Pay $200M for ‘Systemic Wage Violations’
More than 33,000 Providence employees filed a class-action complaint against the health system in 2021, alleging that it had been withholding their wages by denying them breaks and rounding down their working hours. Last week, Providence was ordered to pay more than $200 million in damages — a decision that “sends a message to healthcare corporations,” according to an attorney representing the workers.
FDA Drug Approval Marks a New Day for Treating Pediatric Brain Cancer
Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer.